HK Stock Market Move | GENFLEET-B(02595) rose over 6% in the morning. CDE has accepted the clinical application of GDF15/IL-6 dual-antibody injection.
JF Pharma-B (02595) surged over 6% in the morning session, up 5.08% as of the time of writing, at HK$35.96, with a turnover of HK$168.163 million.
GENFLEET-B(02595) rose more than 6% in the morning and, as of the time of writing, was up 5.08%, trading at 35.96 Hong Kong dollars with a trading volume of 1681.63 million Hong Kong dollars.
On the news front, the latest announcement on the CDE official website shows that the clinical trial application for GFS202A injection submitted by Jin Fang Pharmaceutical has officially been accepted on May 12th, with the acceptance number CXSL2600491. Public information shows that GFS202A is the world's first dual-specific antibody targeting GDF15 and IL-6.
Southwest released a research report stating that the company is entering the large indications market such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product matrix, aiming to cover 1L and various line treatments, with global-leading product progress. It is expected that the revenue for 2026-2028 will be 0.85/1.02/3.11 billion yuan respectively, with year-on-year changes of -35%/+20%/+205%. We recommend paying close attention.
Related Articles
GEELY AUTO (00175) issued 100,000 shares due to the exercise of warrants.
TASTEGOURMET GP (08371): Feng Haixin appointed as Chief Financial Officer
.png)
HK Stock Market Move | LAOPU GOLD (06181) falls by more than 5% again. Institutions point out that the short-term data of SKP Mall cannot represent the overall performance of same-store sales.
GEELY AUTO (00175) issued 100,000 shares due to the exercise of warrants.
TASTEGOURMET GP (08371): Feng Haixin appointed as Chief Financial Officer
HK Stock Market Move | LAOPU GOLD (06181) falls by more than 5% again. Institutions point out that the short-term data of SKP Mall cannot represent the overall performance of same-store sales.
